The EGR1 (Early Growth Response Protein 1) antibody is a crucial tool for studying the EGR1 transcription factor, which plays a pivotal role in regulating gene expression in response to extracellular signals. EGR1. encoded by the EGR1 gene, belongs to the zinc-finger transcription factor family and is rapidly induced by growth factors, stress, or cellular differentiation cues. It regulates genes involved in cell proliferation, apoptosis, and tissue remodeling.
Antibodies targeting EGR1 are widely used in research to detect and quantify EGR1 protein levels in various experimental models, including Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and chromatin immunoprecipitation (ChIP). These applications help elucidate EGR1’s role in physiological processes (e.g., neuronal development, immune response) and pathologies such as cancer, cardiovascular diseases, and neurological disorders.
EGR1 dysregulation is linked to tumor progression, fibrosis, and inflammation, making its antibody valuable in biomarker studies. Commercial EGR1 antibodies are typically raised against specific epitopes (e.g., N-terminal or C-terminal regions) in hosts like rabbits or mice. Validation includes testing for specificity via knockout controls or siRNA knockdown.
Researchers prioritize antibodies with high specificity and low cross-reactivity to related family members (EGR2-4). As EGR1’s activity is context-dependent, its antibody serves as a key reagent in dissecting signaling pathways and transcriptional networks in health and disease.